CLINICAL_TRIALS
trial_result
· 2020-07-07
Clinical Trial Update: DC Vaccination for Post-remission Therapy in AML [Phase 1, Phase 2]
Summary
Phase 1/2 clinical trial investigating dendritic cell vaccination as post-remission therapy in acute myeloid leukemia has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Medigene AG | Conditions: Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: COMPLETED